Ignite Creation Date:
2024-05-06 @ 5:37 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05376800
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-05-03
Brief Title:
A Study to Determine How BI 907828 Brigimadlin is Taken up in the Tumor Phase 0 and to Determine the Highest Dose of BI 907828 Brigimadlin That Could be Tolerated Phase 1a in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2027-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-20
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-03
First Submit QC Date:
May 16 2022
Study First Post Date:
2022-05-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-05
Last Update Post Date:
2024-04-18
Last Update Post Date Type:
ACTUAL